肟类药物治疗神经性毒剂中毒的路径——从实验研究到重症监护病房
本文为叙述性综述,聚焦神经性毒剂中毒,基于作者多年实验研究并结合文献,阐述不同有机磷化合物对乙酰胆碱酯酶抑制动力学、抑制后反应及肟诱导重活化的影响,并讨论种属差异对动物实验外推至人的重要性。文章还综述了监测有机磷中毒或检测皮肤暴露的工具,以及将体外静态与动态测试系统整合进临床管理的案例。结论指出肟类治疗成功取决于有机磷化合物的理化与毒代动力学特性、暴露途径、剂量、皮肤洗消、其他解毒剂给药及包括机械通气在内的急救治疗等多参数。
要点
- 吸入神经性毒剂蒸气后症状可极快出现,数分钟内即可死亡;经皮暴露后临床体征出现可能延迟。
- 有机磷中毒致死机制包括呼吸肌与延髓呼吸中枢麻痹、支气管收缩及支气管溢液,可迅速导致死亡。
- 当前药物治疗包括阿托品、肟类和苯二氮䓬类;肟类通过重活化被有机磷抑制的乙酰胆碱酯酶发挥作用。
- 肟类疗效取决于有机磷化合物的理化与毒代动力学特性、暴露途径、剂量、皮肤洗消、其他解毒剂给药及包括机械通气在内的急救治疗。
- 基于Ellman分光光度法的静态体外测试系统可测定有机磷化合物的抑制效力、抑制后反应及肟诱导重活化,另有实时乙酰胆碱酯酶活性测定、动力学计算机建模和肌力测定建模等动态模型。
适用人群与场景
- 神经性毒剂中毒患者,涵盖吸入蒸气暴露与经皮暴露两种途径。
- 军事人员与民用卫生部门中有机磷中毒人群。
处置流程与药物剂量
- 当前药物治疗包括阿托品、肟类和苯二氮䓬类;肟类通过重活化被有机磷抑制的乙酰胆碱酯酶发挥作用。
- 急救治疗包括皮肤洗消、其他解毒剂给药及机械通气。
- 可将动态计算机模型与胆碱酯酶状态整合进临床治疗,如对硫磷中毒个案所示。
- 可利用皮肤上毒性乙酰胆碱酯酶抑制剂检测工具、胆碱酯酶状态及神经肌肉传递测定进行实验室诊断与治疗监测。
红旗征与不能漏的情况
- 吸入神经性毒剂蒸气后症状可极快出现,数分钟内即可死亡。
- 呼吸肌与延髓呼吸中枢麻痹、支气管收缩及支气管溢液可迅速导致死亡。
- 经皮暴露后临床体征出现可能延迟。
研究设计与关键结果
- 本文为叙述性综述,主要基于作者多年广泛研究并补充适当文献,聚焦神经性毒剂中毒。
- 有机磷化合物包括神经性毒剂与农药,具有共同通式;结构及理化性质差异导致内在毒性以及临床症状起始、严重程度和持续时间的不同。
- 最相关的毒理学机制为抑制乙酰胆碱酯酶,导致神经肌肉接头及中枢和自主神经系统胆碱能突触过度刺激。
- 基于Ellman分光光度法开发了静态体外测试系统,用于测定有机磷化合物的抑制效力、抑制后反应及肟诱导重活化。
- 综述了动态模型,包括实时测定乙酰胆碱酯酶活性、动力学计算机建模及用于测定肌力的建模。
- 综述了评估正性别构调节剂降低或逆转烟碱型乙酰胆碱受体脱敏效力的研究。
- 通过一项临床研究展示神经肌肉传递与乙酰胆碱酯酶活性之间的联系,并通过对硫磷中毒单个患者病例报告展示动态计算机模型与胆碱酯酶状态整合进临床治疗。
证据类型、等级与局限
- 证据类型:叙述性综述,主要基于作者多年实验研究并补充文献。
- 局限:原文未报告局限性。
对床旁实践的改变
- 肟类治疗成功取决于有机磷化合物的理化与毒代动力学特性、暴露途径、剂量、皮肤洗消、其他解毒剂给药及包括机械通气在内的急救治疗等多参数,床旁决策需综合评估这些因素。
- 酶水平测试系统及复杂人与动物组织实验有助于更广泛了解肟类有效性及中毒与肟类治疗期间发生的事件。
- 种属差异对动物实验外推至人具有重要性,解读动物实验结果时需考虑。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Organophosphorus poisoning is still a continuing threat to military forces and the civilian health sector. The therapeutic value of clinically used oxime antidotes is frequently a matter of controversy. In this narrative review, we will focus on nerve agent poisoning in particular and show how experimental results can be integrated into the therapy of patients.
METHODS: This narrative review is based primarily on the extensive studies conducted by the authors over many years, supplemented by appropriate literature to provide the reader with currently available knowledge of the effects of different organophosphorus compounds on the inhibition kinetics, the post-inhibitory reactions and oxime-induced reactivation. The importance of species differences for the translation of animal experiments to humans is discussed by means of suitable published studies. The literature that describes tools that enable the monitoring of organophosphorus compound poisoning or the detection of skin exposure to organophosphorus compounds is reviewed.
ORGANOPHOSPHORUS COMPOUNDS: STRUCTURE AND CHARACTERISTICS: Organophosphorus compounds, including nerve agents and pesticides, have a common general formula. In consequence, the variations in the structure and the physicochemical properties result in differences in the intrinsic toxicity of organophosphorus compounds as well as the onset, severity, and duration of clinical symptoms.
MECHANISMS OF ORGANOPHOSPHORUS POISONING: The most toxicologically relevant mechanism of organophosphorus compounds is the inhibition of acetylcholinesterase, resulting in the overstimulation of cholinergic synapses in the neuromuscular junction as well as the central and the autonomic nervous system.
SIGNS AND SYMPTOMS OF ORGANOPHOSPHORUS POISONING: After exposure by inhalation to nerve agent vapour, symptoms may develop very fast, and death can occur within minutes. The paralysis of respiratory muscles and the medullary respiratory centre, as well as bronchoconstriction and bronchorrhoea, may lead to death rapidly. In contrast, the onset of clinical signs may be delayed after percutaneous exposure.
TREATMENT OF ORGANOPHOSPHORUS POISONING: Current medical therapy includes atropine, oximes, and benzodiazepines. Oximes act by the reactivation of organophosphorus-inhibited acetylcholinesterase.
TEST SYSTEMS FOR THE INVESTIGATION OF INTERACTIONS BETWEEN ORGANOPHOSPHORUS COMPOUNDS AND ACETYLCHOLINESTERASE: Based on the spectrophotometric Ellman assay, static in vitro test systems for the determination of the inhibitory potency of an organophosphorus compound, post-inhibitory reactions, and oxime-induced reactivation have been developed, and their value is assessed. In addition, several dynamic models (real-time determination of acetylcholinesterase activity, kinetic computer modeling, and modeling for the determination of muscle force) are reviewed.
INNOVATIVE: in vitro experimental approaches and promising therapeutic strategies: Studies assessing the potency of positive allosteric modulators to reduce or reverse the desensitization of the nicotinic acetylcholine receptor are reviewed.
TEST SYSTEMS FOR THE LABORATORY DIAGNOSIS OF ORGANOPHOSPHORUS EXPOSURE AND THE THERAPEUTIC MONITORING OF PATIENTS POISONED WITH ORGANOPHOSPHORUS COMPOUNDS: A tool to detect toxic inhibitors of acetylcholinesterase on the skin, cholinesterase status as well as the determination of neuromuscular transmission in organophosphorus poisoning are described.
THE INTEGRATION OF TEST SYSTEMS INTO THE MANAGEMENT OF CASES OF ORGANOPHOSPHORUS POISONING: A clinical study is used to demonstrate the connection between neuromuscular transmission and acetylcholinesterase activity. Case reports of single patients with parathion poisoning are presented, showing the integration of the dynamic computer model and the cholinesterase status into clinical treatment.
CONCLUSIONS: The success of oxime therapy depends on various parameters, such as the physicochemical and toxicokinetic properties of organophosphorus compounds, the route of exposure, the dose, skin decontamination, administration of other antidotes, and emergency treatment, including mechanical ventilation. Various test systems at the enzyme level and experiments with complex human and animal tissues are available to obtain a broader knowledge of the effectiveness of oximes and a comprehensive understanding of events occurring during poisoning and oxime therapy.
参考来源
- Thiermann H, Worek F, Horn G, et al. Approaches to the treatment of nerve agent poisoning with oximes - from experimental studies to the intensive care unit. Clin Toxicol (Phila). 2025. PMID: 40421756. doi:10.1080/15563650.2025.2501266
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。